Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 8Plasma cell 4Other hematologic neoplasm 2Thoracic 1Other solid neoplasm 1Myeloid 1Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 88pembrolizumab 77Pemetrexed 65Cisplatin 56Paclitaxel 33Docetaxel 31durvalumab 28atezolizumab 28Nivolumab 28Specimen Handling 25Magnetic Resonance Spectroscopy 20Gemcitabine 19osimertinib 18130-nm albumin-bound paclitaxel 18Etoposide 17Radiotherapy 14Cetuximab 14Platinum 12Taxes 11Immunoglobulin G 101,2-diaminocyclohexaneplatinum II citrate 10Radiation 9Ipilimumab 9Disulfides 9Bevacizumab 9amivantamab 8Topotecan 8fludarabine 7Ramucirumab 7Radiosurgery 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
tocilizumab × Thoracic × 30 days × Clear all
NCT07594067 2026-05-18

TCR1188-ABC Cells in KRAS-mutated Cancers

University of Pennsylvania

Phase 1 Not yet recruiting
30 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡